| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
From the Cutaneous Biology Research Center* and the Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Massachusetts; the Weatherall Institute of Molecular Medicine, John Radcliffe Hospital, Headington, Oxford, United Kingdom; and the Institute of Pharmaceutical Sciences, Swiss Federal Institute of Technology Zurich, Zurich, Switzerland
The mucin-type glycoprotein podoplanin is specifically expressed by lymphatic but not blood vascular endothelial cells in culture and in tumor-associated lymphangiogenesis, and podoplanin deficiency results in congenital lymphedema and impaired lymphatic vascular patterning. However, research into the biological importance of podoplanin has been hampered by the lack of a generally available antibody against the human protein, and its expression in normal tissues and in human malignancies has remained unclear. We generated a human podoplanin-Fc fusion protein and found that the commercially available mouse monoclonal antibody D2-40 specifically recognized human podoplanin, as assessed by enzyme-linked immunosorbent assay and Western blot analyses. We found that, in addition to lymphatic endothelium, podoplanin was also expressed by peritoneal mesothelial cells, osteocytes, glandular myoepithelial cells, ependymal cells, and by stromal reticular cells and follicular dendritic cells of lymphoid organs. These findings were confirmed in normal mouse tissues with anti-podoplanin antibody 8.1.1. Podoplanin was also strongly expressed by granulosa cells in normal ovarian follicles, and by ovarian dysgerminomas and granulosa cell tumors. Although podoplanin was primarily absent from normal human epidermis, its expression was strongly induced in 22 of 28 squamous cell carcinomas studied. These findings suggest a potential role of podoplanin in tumor progression, and they also identify the first commercially available antibody for the specific staining of a defined lymphatic marker in archival human tissue sections, thereby enabling more widespread studies of tumor lymphangiogenesis in human cancers.
This article has been cited by other articles:
 |
|
 |
|
  Y. Watanabe, T. Hamanaka, T. Takemura, and A. Murakami Involvement of Platelet Coagulation and Inflammation in the Endothelium of Schlemm's Canal Invest. Ophthalmol. Vis. Sci., January 1, 2010; 51(1): 277 - 283. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Hirakawa, M. Detmar, D. Kerjaschki, S. Nagamatsu, K. Matsuo, A. Tanemura, N. Kamata, K. Higashikawa, H. Okazaki, K. Kameda, et al. Nodal Lymphangiogenesis and Metastasis: Role of Tumor-Induced Lymphatic Vessel Activation in Extramammary Paget's Disease Am. J. Pathol., November 1, 2009; 175(5): 2235 - 2248. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Kambouchner and J.-F. Bernaudin Intralobular Pulmonary Lymphatic Distribution in Normal Human Lung Using D2-40 Antipodoplanin Immunostaining J. Histochem. Cytochem., July 1, 2009; 57(7): 643 - 648. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Peduto, S. Dulauroy, M. Lochner, G. F. Spath, M. A. Morales, A. Cumano, and G. Eberl Inflammation Recapitulates the Ontogeny of Lymphoid Stromal Cells J. Immunol., May 1, 2009; 182(9): 5789 - 5799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Durchdewald, J. Guinea-Viniegra, D. Haag, A. Riehl, P. Lichter, M. Hahn, E. F. Wagner, P. Angel, and J. Hess Podoplanin Is a Novel Fos Target Gene in Skin Carcinogenesis Cancer Res., September 1, 2008; 68(17): 6877 - 6883. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. N. Vanderbilt, L. Allen, R. F. Gonzalez, Z. Tigue, J. Edmondson, D. Ansaldi, A. M. Gillespie, and L. G. Dobbs Directed Expression of Transgenes to Alveolar Type I Cells in the Mouse Am. J. Respir. Cell Mol. Biol., September 1, 2008; 39(3): 253 - 262. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Nakazawa, S. Sato, M. Naito, Y. Kato, K. Mishima, H. Arai, T. Tsuruo, and N. Fujita Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis Blood, September 1, 2008; 112(5): 1730 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Koop, M. Eikmans, M. Wehland, H. Baelde, D. Ijpelaar, R. Kreutz, H. Kawachi, D. Kerjaschki, E. de Heer, and J. A. Bruijn Selective Loss of Podoplanin Protein Expression Accompanies Proteinuria and Precedes Alterations in Podocyte Morphology in a Spontaneous Proteinuric Rat Model Am. J. Pathol., August 1, 2008; 173(2): 315 - 326. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Niakosari, H. J. Kahn, D. McCready, D. Ghazarian, L. E. Rotstein, A. Marks, A. Kiss, and L. From Lymphatic Invasion Identified by Monoclonal Antibody D2-40, Younger Age, and Ulceration: Predictors of Sentinel Lymph Node Involvement in Primary Cutaneous Melanoma Arch Dermatol, April 1, 2008; 144(4): 462 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L Browning, D Bailey, and A Parker D2-40 is a sensitive and specific marker in differentiating primary adrenal cortical tumours from both metastatic clear cell renal cell carcinoma and phaeochromocytoma J. Clin. Pathol., March 1, 2008; 61(3): 293 - 296. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Kajiya, R. Huggenberger, I. Drinnenberg, B. Ma, and M. Detmar Nitric oxide mediates lymphatic vessel activation via soluble guanylate cyclase {alpha}1{beta}1-impact on inflammation FASEB J, February 1, 2008; 22(2): 530 - 537. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Kawaguchi, A. K. El-Naggar, V. Papadimitrakopoulou, H. Ren, Y.-H. Fan, L. Feng, J. J. Lee, E. Kim, W. K. Hong, S. M. Lippman, et al. Podoplanin: A Novel Marker for Oral Cancer Risk in Patients With Oral Premalignancy J. Clin. Oncol., January 20, 2008; 26(3): 354 - 360. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B S M S Siriwardena, Y Kudo, I Ogawa, M N G P K Udagama, W M Tilakaratne, and T Takata VEGF-C is associated with lymphatic status and invasion in oral cancer J. Clin. Pathol., January 1, 2008; 61(1): 103 - 108. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Suzuki-Inoue, Y. Kato, O. Inoue, M. K. Kaneko, K. Mishima, Y. Yatomi, Y. Yamazaki, H. Narimatsu, and Y. Ozaki Involvement of the Snake Toxin Receptor CLEC-2, in Podoplanin-mediated Platelet Activation, by Cancer Cells J. Biol. Chem., September 7, 2007; 282(36): 25993 - 26001. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A B Soares, L Ponchio, P B Juliano, V C de Araujo, and A Altemani Lymphatic vascular density and lymphangiogenesis during tumour progression of carcinoma ex pleomorphic adenoma J. Clin. Pathol., September 1, 2007; 60(9): 995 - 1000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Bock, J. Onderka, T. Dietrich, B. Bachmann, F. E. Kruse, M. Paschke, G. Zahn, and C. Cursiefen Bevacizumab as a Potent Inhibitor of Inflammatory Corneal Angiogenesis and Lymphangiogenesis Invest. Ophthalmol. Vis. Sci., June 1, 2007; 48(6): 2545 - 2552. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. F. Donoghue, F. L. Lederman, B. J. Susil, and P. A.W. Rogers Lymphangiogensis of normal endometrium and endometrial adenocarcinoma Hum. Reprod., June 1, 2007; 22(6): 1705 - 1713. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. K. McColl, K. Paavonen, T. Karnezis, N. C. Harris, N. Davydova, J. Rothacker, E. C. Nice, K. W. Harder, S. Roufail, M. L. Hibbs, et al. Proprotein convertases promote processing of VEGF-D, a critical step for binding the angiogenic receptor VEGFR-2 FASEB J, April 1, 2007; 21(4): 1088 - 1098. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Kunita, T. G. Kashima, Y. Morishita, M. Fukayama, Y. Kato, T. Tsuruo, and N. Fujita The Platelet Aggregation-Inducing Factor Aggrus/Podoplanin Promotes Pulmonary Metastasis Am. J. Pathol., April 1, 2007; 170(4): 1337 - 1347. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Heller, M. T. Lindenmeyer, C. D. Cohen, U. Brandt, D. Draganovici, M. Fischereder, M. Kretzler, H.-J. Anders, T. Sitter, I. Mosberger, et al. The Contribution of B Cells to Renal Interstitial Inflammation Am. J. Pathol., February 1, 2007; 170(2): 457 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Harrell, B. M. Iritani, and A. Ruddell Tumor-Induced Sentinel Lymph Node Lymphangiogenesis and Increased Lymph Flow Precede Melanoma Metastasis Am. J. Pathol., February 1, 2007; 170(2): 774 - 786. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Kamo, K. Yasuchika, H. Fujii, T. Hoppo, T. Machimoto, T. Ishii, N. Fujita, T. Tsuruo, J. K. Yamashita, H. Kubo, et al. Two populations of Thy1-positive mesenchymal cells regulate in vitro maturation of hepatic progenitor cells Am J Physiol Gastrointest Liver Physiol, February 1, 2007; 292(2): G526 - G534. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Martin-Villar, D. Megias, S. Castel, M. M. Yurrita, S. Vilaro, and M. Quintanilla Podoplanin binds ERM proteins to activate RhoA and promote epithelial-mesenchymal transition J. Cell Sci., November 1, 2006; 119(21): 4541 - 4553. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K J Butnor My approach to the diagnosis of mesothelial lesions. J. Clin. Pathol., June 1, 2006; 59(6): 564 - 574. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Fiedler, S. Christian, S. Koidl, D. Kerjaschki, M. S. Emmett, D. O. Bates, G. Christofori, and H. G. Augustin The Sialomucin CD34 Is a Marker of Lymphatic Endothelial Cells in Human Tumors Am. J. Pathol., March 1, 2006; 168(3): 1045 - 1053. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Gombos, X. Xu, C. S. Chu, P. J. Zhang, and G. Acs Peritumoral Lymphatic Vessel Density and Vascular Endothelial Growth Factor C Expression in Early-Stage Squamous Cell Carcinoma of the Uterine Cervix Clin. Cancer Res., December 1, 2005; 11(23): 8364 - 8371. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Renyi-Vamos, J. Tovari, J. Fillinger, J. Timar, S. Paku, I. Kenessey, G. Ostoros, L. Agocs, I. Soltesz, and B. Dome Lymphangiogenesis Correlates with Lymph Node Metastasis, Prognosis, and Angiogenic Phenotype in Human Non-Small Cell Lung Cancer Clin. Cancer Res., October 15, 2005; 11(20): 7344 - 7353. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
